BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11043831)

  • 1. Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
    Stabuc B; Markovic A; Plesnicar A; Cizej TE
    Neoplasma; 2000; 47(4):248-52. PubMed ID: 11043831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
    Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
    Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
    Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
    Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
    Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
    Sugano K; Ota K; Taguchi T; Ogawa N; Kurihara M; Akazawa S; Ogawa M; Tominaga T; Sasaki T; Konishi T
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):627-37. PubMed ID: 7717714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
    Baur M; Schlappack O; Havelec L; Mader R; Marosi C; Scheithauer W; Dittrich C
    Wien Klin Wochenschr; 1991; 103(11):332-9. PubMed ID: 1858384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
    Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
    Konishi K; Yabushita K; Taguchi T; Ota J; Takashima S; Abe T; Kikkawa N; Yasutomi M; Sowa M; Maehara Y
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):925-32. PubMed ID: 7793998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
    Sobrero AF; Aschele C; Guglielmi AP; Mori AM; Tixi LM; Bolli EA; Rosso R; Mammoliti S; Rollandi GA; Bertoglio S
    Clin Cancer Res; 1995 Sep; 1(9):955-60. PubMed ID: 9816066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.